Trial Profile

Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Single Center, Randomized, Placebo Controlled, Double-blind Phase 2 Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary)
Indications Intestinal pseudo-obstruction
Focus Therapeutic Use

Most Recent Events

11 Oct 2022 Primary endpoint has not been met. (percent improvement in the GSS-abdominal distension score (score 0 or 1), as per Results presented at the 30th United European Gastroenterology Week, as per Results presented at the 30th United European Gastroenterology Week
11 Oct 2022 Results presented at the 30th United European Gastroenterology Week
18 Jun 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com